Back to top
more

WAVE Life Sciences (WVE)

(Delayed Data from NSDQ)

$14.20 USD

14.20
1,375,612

+0.36 (2.60%)

Updated Nov 6, 2024 04:00 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value F Growth C Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 35% (89 out of 251)

Industry: Medical - Biomedical and Genetics

Zacks News

Wave Life Sciences (WVE) Reports Q3 Loss, Misses Revenue Estimates

Wave Life Sciences (WVE) delivered earnings and revenue surprises of 12.50% and 94.80%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Heska (HSKA) Q3 Earnings and Revenues Lag Estimates

Heska (HSKA) delivered earnings and revenue surprises of -8.89% and 11.80%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Selecta Biosciences, Inc. (SELB) Reports Q3 Loss, Lags Revenue Estimates

Selecta Biosciences, Inc. (SELB) delivered earnings and revenue surprises of -200% and 37.24%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Wave Life Sciences (WVE) Soars 13.8%: Is Further Upside Left in the Stock?

Wave Life Sciences (WVE) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Wave Therapeutics (WVE) Up on Update From Huntington's Study

Wave Therapeutics (WVE) provides a positive update from its ongoing phase Ib/IIa study evaluating one of its lead candidates, WVE-003, for Huntington's disease. Stock up.

Wave Life Sciences (WVE) Reports Q2 Loss, Lags Revenue Estimates

Wave Life Sciences (WVE) delivered earnings and revenue surprises of -10.71% and 88.46%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Mirati (MRTX) Reports Q2 Loss, Tops Revenue Estimates

Mirati (MRTX) delivered earnings and revenue surprises of 9.92% and 143.73%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Wave Life Sciences (WVE) Reports Q1 Loss, Lags Revenue Estimates

Wave Life Sciences (WVE) delivered earnings and revenue surprises of -10.71% and 53.33%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Wave Life Sciences (WVE) Reports Q4 Loss, Misses Revenue Estimates

Wave Life Sciences (WVE) delivered earnings and revenue surprises of -29.79% and 90.27%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Albireo Pharma (ALBO) Reports Q4 Loss, Tops Revenue Estimates

Albireo Pharma (ALBO) delivered earnings and revenue surprises of 55.12% and 164.33%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Adaptive Biotechnologies (ADPT) Reports Q4 Loss, Tops Revenue Estimates

Adaptive Biotechnologies (ADPT) delivered earnings and revenue surprises of 0% and 5.13%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Wave Life Sciences (WVE) Reports Q3 Loss, Tops Revenue Estimates

Wave Life Sciences (WVE) delivered earnings and revenue surprises of 81.25% and 240.40%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Will Wave Life Sciences (WVE) Report Negative Q3 Earnings? What You Should Know

Wave Life Sciences (WVE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

New Strong Sell Stocks for October 22nd

BNFT, EXN, RACE, LLNW, and WVE have been added to the Zacks Rank #5 (Strong Sell) List on October 22, 2021.

Wave Life Sciences (WVE) Reports Q2 Loss, Misses Revenue Estimates

Wave Life Sciences (WVE) delivered earnings and revenue surprises of -27.87% and -76.67%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

Wave Life Sciences (WVE) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

Wave Life Sciences (WVE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Wave Life Sciences (WVE) Reports Q1 Loss, Misses Revenue Estimates

Wave Life Sciences (WVE) delivered earnings and revenue surprises of -53.57% and -100.00%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

Are Options Traders Betting on a Big Move in Wave Life Sciences (WVE) Stock?

Investors need to pay close attention to Wave Life Sciences (WVE) stock based on the movements in the options market lately.

Solid Biosciences (SLDB) Announces DMD Study Data, Stock Down

Solid Biosciences' (SLDB) lead gene therapy candidate achieves positive improvements in DMD patients. However, it fails to cheer investors.

Wave Life Sciences (WVE) Reports Q4 Loss, Lags Revenue Estimates

Wave Life Sciences (WVE) delivered earnings and revenue surprises of -7.27% and -30.61%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

Will Wave Life Sciences (WVE) Report Negative Q4 Earnings? What You Should Know

Wave Life Sciences (WVE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Wave Life Sciences (WVE) Reports Q3 Loss, Misses Revenue Estimates

Wave Life Sciences (WVE) delivered earnings and revenue surprises of -17.81% and -76.49%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

Wave Life Sciences (WVE) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release

Wave Life Sciences (WVE) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Sweta Killa headshot

Healthcare ETFs, Stocks That Gained Double Digits Last Week

The healthcare sector defied last week's market rout buoyed by the progress in the development of a coronavirus vaccine or treatment, and merger and acquisition news.

Implied Volatility Surging for Wave Life Sciences (WVE) Stock Options

Investors need to pay close attention to Wave Life Sciences (WVE) stock based on the movements in the options market lately.